

# Lead Compound Identification of CD171 ADC for Solid Tumor Treatment

APITBIO, Inc.

|                         |   |
|-------------------------|---|
| Disease Area            | Oncology  |
| Product Type            | Drug-conjugate  |
| Indication              | CD171 (L1CAM)-positive Solid tumor  |
| Target                  | CD171 (L1CAM)   |
| Mechanism of Action     | Binding to CD171 (L1CAM) → Internalization → Cleaved and released active payload in lysosome → Cancer cell death by payload   |
| Competitiveness         | <ul style="list-style-type: none"><li>Class: First-in-class.</li><li>Anti-CD171 mAb (Ab612): Phase I IND approval in KOREA, Completion of GMP production process in 500 L scale.</li><li>Ab612-MMAE (IC50): 100-fold lower than Kadcylla in HER2 (+) breast cancer cells, Excellent cytotoxicity in HER2 (low) and TNBC.</li><li>Ab612-MMAE, Ab612-Dxd: Similar in vivo efficacy with Enhertu in JIMT-1-bearing CDX mouse model, Excellent stability.</li></ul> |
| Development Stage       | Lead  |
| Route of Administration | Intravenous infusion  |
| Key Data                |   |